Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Jan;299(1):105-112.
doi: 10.1007/s00404-018-4942-y. Epub 2018 Oct 29.

Clinical experience with misoprostol vaginal insert for induction of labor: a prospective clinical observational study

Affiliations
Observational Study

Clinical experience with misoprostol vaginal insert for induction of labor: a prospective clinical observational study

Markus Schmidt et al. Arch Gynecol Obstet. 2019 Jan.

Abstract

Purpose: To provide real-world evidence using misoprostol vaginal insert (MVI) for induction of labor in nulliparous and parous women at two German Level I Centers in a prospective observational study.

Methods: Between 1 August 2014 and 1 October 2015, eligible pregnant women (≥ 36 + 0 weeks of gestation) requiring labor induction were treated with MVI. Endpoints included time to and mode of delivery rates of tocolysis use, tachysystole, uterine hypertonus or uterine hyperstimulation syndrome and newborn outcomes.

Results: Of the 354 women enrolled, 68.9% (244/354) achieved vaginal delivery (nulliparous, 139/232 [59.9%]; parous 105/122 [86.1%]; p < 0.001). Median time from MVI administration to vaginal delivery was 14.0 h (nulliparous, 14.5 h; parous, 11.9 h; p < 0.001). A total of 205/244 (84.0%) and 228/244 (93.4%) women achieved a vaginal delivery within 24 h and 30 h, respectively. The most common indications for cesarean delivery were pathologic cardiotocography (nulliparous, 41/232 [17.4%]; parous, 13/122 [10.7%]; p = 0.081) and arrested labor (dilation or descent; nulliparous, 45/232 [19.4%], parous, 3/122 [2.5%]; p ≤ 0.001). A total of 24.3% of women experienced uterine tachysystole and 9.6% experienced uterine tachysystole with fetal heart rate involvement, neither of which were significantly different for nulliparous and parous women. In total, 42/345 (12.2%) of the neonates had an arterial pH < 7.15 and 12/345 3.5% had a 5-min Apgar score ≤ 7.

Conclusion: When clinically indicated, MVI was efficient and safe for induction of labor in women with an unfavorable cervix. Women, however, should be counseled regarding the risk of uterine tachysystole prior to labor induction with MVI.

Keywords: Induction of labor; Misoprostol; Misoprostol vaginal insert; Mode of delivery; Prostaglandin E1; Time to delivery; Vaginal delivery.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committees (Ethics Committee of the Department of Medicine of the Philipps-University Marburg and Ethics Committee of the Department of Medicine for the University of Duisburg-Essen: #15-6545-BO, approved August 27, 2015) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Figures

Fig. 1
Fig. 1
Time to vaginal delivery

Similar articles

Cited by

References

    1. Justus Hofmeyr G. Induction of labour with an unfavourable cervix. Best Pract Res Clin Obstet Gynaecol. 2003;17(5):777–794. doi: 10.1016/S1521-6934(03)00037-3. - DOI - PubMed
    1. Tenore JL. Methods for cervical ripening and induction of labor. Am Fam Physician. 2003;67(10):2123–2128. - PubMed
    1. Sanchez-Ramos L. Induction of labor. Obstet Gynecol Clin North Am. 2005;32(2):181–200. doi: 10.1016/j.ogc.2004.12.004. - DOI - PubMed
    1. Wagner M. Off-label use of misoprostol in obstetrics: a cautionary tale. BJOG. 2005;112(3):266–268. doi: 10.1111/j.1471-0528.2004.00445.x. - DOI - PubMed
    1. Mysodelle 200 micrograms vaginal delivery system SmPC. https://www.medicines.org.uk/emc/product/3436/smpc. Accessed 26 Oct 2018

Publication types